Serum GP73, a Marker for Evaluating Progression in Patients with Chronic HBV Infections

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Wei, Hongshan ^a   Li, Boan ^b   Zhang, Renwen ^a   Hao, Xiaohua ^a   Huang, Yubo ^a   Qiao, Yong ^a   Hou, Jun ^b   Li, Xin ^a   Li, Xingwang ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b 302 MILITARY HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; GLYCOPROTEIN; GLYCOPROTEIN GP73; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; ELASTOGRAPHY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTERMETHOD COMPARISON; LIVER BIOPSY; LIVER CELL; LIVER FIBROSIS; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; PERFORMANCE MEASUREMENT SYSTEM; POPULATION RESEARCH; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RIGIDITY; SENSITIVITY AND SPECIFICITY;

ADULT; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; FIBROSIS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84873906665     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053862     Document Type: Article

References (31)

1. Teixeira-Clerc F, Julien B, Grenard P, Tran Van Nhieu J, Deveaux V, Li L, et al. (2006) CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 12: 671-696.
2. Tong MJ, Hsien C, Hsu L, Sun HE, Blatt LM, (2008) Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Hepatology 48: 1070-1078.
3. Hoefs JC, Shiffman ML, Goodman ZD, Kleiner DE, Dienstag JL, et al. (2011) Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial. Gastroenterology 141: 900-908.e1-2.
4. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, et al. (2004) Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 10: 429-434.
5. Munteanu M, Imbert-Bismut F, Messous D, Morra R, Thabut D, et al. (2008) Reproducibility of non-invasive fibrosis biomarkers, FibroMeter and FibroTest, could be improved by respecting the analytical standardizations. Clin Biochem 41: 1113-1114.
6. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, et al. (2001) Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357: 1069-1075.
7. Mayo MJ, Parkes J, Adams-Huet B, Combes B, Mills AS, et al. (2008) Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology 48: 1549-1557.
8. Naveau S, Gaudé G, Asnacios A, Agostini H, Abella A, et al. (2009) Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 49: 97-105.
9. Riener MO, Stenner F, Liewen H, Soll C, Breitenstein S, et al. (2009) Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology 49: 1602-1609.
10. Kladney RD, Bulla GA, Guo L, Mason AL, Tollefson AE, et al. (2000) GP73, a novel Golgi-localized protein upregulated by viral infection. Gene 249: 53-65.
11. Liu X, Wan X, Li Z, Lin C, Zhan Y, et al. (2011) Golgi protein 73(GP73), a useful serum marker in liver diseases. Clin Chem Lab Med 49: 1311-1316.
12. Iftikhar R, Kladney RD, Havlioglu N, Schmitt-Gräff A, Gusmirovic I, et al. (2004) Disease- and cell-specific expression of GP73 in human liver disease. Am J Gastroenterol 99: 1087-1095.
13. Sun Y, Yang H, Mao Y, Xu H, Zhang J, et al. (2011) Increased Golgi protein 73 expression in hepatocellular carcinoma tissue correlates with tumor aggression but not survival. J Gastroenterol Hepatol 26: 1207-1212.
14. Castera L, Forns X, Alberti A, (2008) Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 48: 835-847.
15. Corpechot C, Carrat F, Poujol-Robert A, Gaouar F, Wendum D, et al. (2012) Noninvasive elastography-based assessment of liver fibrosis progressionand prognosis in primary biliary cirrhosis. Hepatology 56(1): 198-208.
16. Bedossa P, Poynard T, (1996) An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24: 289-293.
17. Cao Q, Mak KM, Lieber CS, (2007) Leptin represses matrix metalloproteinase-1 gene expression in LX2 human hepatic stellate cells. J Hepatol 46(1): 124-33.
18. Alberti A, Caporaso N, (2011) HBV therapy: guidelines and open issues. Dig Liver Dis 43Suppl 1: S57-63.
19. Adams LA, George J, Bugianesi E, Rossi E, De Boer WB, et al. (2011) Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. J Gastroenterol Hepato 26 (10): 1536-1543.
20. Tian L, Wang Y, Xu D, Gui J, Jia X, et al. (2011) Serological AFP/golgi protein 73 could be a new diagnostic parameter of hepatic diseases. Int J Cancer 129(8): 1923-1931.
21. Gu Y, Chen W, Zhao Y, Chen L, Peng T, (2009) Quantitative analysis of elevated serum Golgi protein-73 expression in patients with liver diseases. Ann Clin Biochem 46: 38-43.
22. Wright LM, Huster D, Lutsenko S, Wrba F, Ferenci P, et al. (2009) Hepatocyte GP73 expression in Wilson disease. J Hepatol 51: 557-564.
23. Maitra A, Thuluvath PJ, (2004) GP73 and liver disease: a (Golgi) complex enigma. Am J Gastroenterol 99(6): 1096-1098.
24. Zoulim F, Perrillo R, (2008) Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 48Suppl 1: S2-19.
25. Sebagh M, Samuel D, Antonini TM, Coilly A, Degli Esposti D, et al. (2012) Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients. J Hepatol 56: 840-847.
26. Poynard T, Ngo Y, Perazzo H, Munteanu M, Lebray P, et al. (2011) Prognostic value of liver fibrosis biomarkers: a meta-analysis. Gastroenterol Hepatol (N Y) 7: 445-454.
27. Guha IN, Myers RP, Patel K, Talwalkar JA, (2011) Biomarkers of liver fibrosis: what lies beneath the receiver operating characteristic curve? Hepatolog 54: 1454-1462.
28. Stabinski L, Reynolds SJ, Ocama P, Laeyendecker O, Ndyanabo A, et al. (2011) High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. Antivir The 16: 405-411.
29. Fung J, Lai CL, But D, Wong D, Cheung TK, et al. (2008) Prevalence of fibrosis and cirrhosis in chronic hepatitis B: implications for treatment and management. Am J Gastroenterol 103: 1421-1426.
30. Wong GL, Wong VW, Chim AM, Yiu KK, Chu SH, et al. (2011) Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population. J Gastroenterol Hepatol 26: 300-305.
31. Wright LM, Yong S, Picken MM, Rockey D, Fimmel CJ, (2009) Decreased survival and hepato-renal pathology in mice with C-terminally truncated GP73 (GOLPH2). Int J Clin Exp Pathol 2: 34-47.